Everolimus is the first generation of mTOR inhibitors, and it is a serine-threonine protein kinase in the mTOR signal pathway, which is an important potential target for cancer therapy [8, 9].Some clinical trials have demonstrated the survival benefit of everolimus in soft tissue sarcomas patients. Here, MTOR is linked to soft tissue sarcoma.